MedTrace Logo

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

NCT05910398 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 488

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Conditions

  • Breast Cancer Invasive

Interventions

DRUG

pyrotinib

an irreversible anti-HER2 tyrosine kinase inhibitor

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Wenjin Yin, M.D. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2030-04-30
Completion
2030-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05910398 on ClinicalTrials.gov